CliffBio
biologic

Jeuveau

prabotulinumtoxinA-xvfs

Loss of exclusivityFebruary 2031projected — 12-year biologic exclusivity estimate
CompanyEvolus →See this company's full patent-cliff portfolio

Drug detail

Brand nameJeuveau
Active ingredientprabotulinumtoxinA-xvfs
Strength100UNITS
Dosage formFor Injection
RouteIntramuscular
ModalityBiologic
FDA approvalFebruary 2019
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.